Key result
Administering paclitaxel before doxorubicin reduced doxorubicin clearance by 32% (34.3 vs 51.6 L/h, P<.01) and resulted in worse stomatitis compared to the reverse sequence.
Why the study?
Does the paclitaxel-doxorubicin sequence alter doxorubicin pharmacokinetics and toxicity compared to the reverse sequence in patients with metastatic breast cancer?
Does the paclitaxel-doxorubicin sequence alter doxorubicin pharmacokinetics and toxicity compared to the reverse sequence in patients with metastatic breast cancer?
Absolute Event Rate: 34.3% vs 51.6%
p-value: p=< .01
Administering paclitaxel before doxorubicin significantly reduces doxorubicin clearance and increases toxicity, indicating doxorubicin should be given first.
No takes yet. Share an insight, caveat, or question.
Doxorubicin before paclitaxel may limit toxicity; leaves open optimal sequencing in metastatic breast cancer.
Holmes et al. (1996) studied Metastatic breast cancer (n=10). Paclitaxel followed by doxorubicin vs. Doxorubicin followed by paclitaxel was evaluated on Mean doxorubicin clearance (p=< .01). Administering paclitaxel before doxorubicin reduced doxorubicin clearance by 32% (34.3 vs 51.6 L/h, P<.01) and resulted in worse stomatitis compared to the reverse sequence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: